Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Varsha Gandhi, PhD, on Ibrutinib

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement




Nov
04
Today In Oncology
Basser Center for BRCA Awards 2026 Global Prize
Triplet Therapy With Abiraterone Improves OS Long-Term in Metastatic Castration-Sensitive Prostate Cancer
Phase III VOLGA Trial Explores Outcomes in Muscle Invasive Bladder Cancer
First-Line Pembrolizumab Improves Progression-Free Survival in dMMR Advanced Endometrial Cancer
Bispecific ADC May Offer New Treatment Option for HR-Positive, HER2-Negative Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo